![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Doubling dolutegravir dosage reduces
HIV persistence markers in ART-treated adults
|
|
|
CROI 2023 Feb 20-23
Céline Fombellida-Lopez1 , Alexander O. Pasternak2 , Aurelija Cicilionyté2 , Nathalie Maes1,4 , Céline Vanwinge1 , Sandra Ormenese1 , Aurélie Ladang1,4 , Etienne Cavalier1,4 , Lee Winchester3 , Courtney V. Fletcher3 , Fabrice Susin4 , Dolores Vaira4 , Marie-Pierre Hayette1,4 , Catherine Reenaers1,4 , Michel Moutschen1,4 , Gilles Darcis1,4
1University of Liège, Liège, Belgium, 2University of Amsterdam, Amsterdam, Netherlands, 3University of Nebraska Medical Center, Omaha, Nebraska, US, 4University Hospital of Liège, Liège, Belgium
![0312231](../images/031223/031223-11/0312231.gif)
![0312232](../images/031223/031223-11/0312232.gif)
![0312233](../images/031223/031223-11/0312233.gif)
![0312234](../images/031223/031223-11/0312234.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|